The new U.S.-U.K. pharmaceutical agreement is an important reminder that there is a smarter way to address global drug-pricing disparities than by importing artificial price controls into the United ...
Forbes contributors publish independent expert analyses and insights. James Broughel is an economist focused on the economics of regulation. Shortages are most damaging when they involve basic ...
ABOUT THE AUTHOR: Allison Schrager is a Bloomberg Opinion columnist covering economics. A senior fellow at the Manhattan Institute, she is author of “An Economist Walks Into a Brothel: And Other ...
For decades, America’s drug-price debate has centered on a fundamental tension: How do policymakers encourage expensive research and development, while ensuring that companies keep final prices ...
The success of political slogans often brings forth intellectual defenders, even when the slogans themselves lack merit. Calls to “freeze the rent” and cap electricity prices before this month’s ...
Mr. Mahoney is an economist and Mr. Ramamurti is a former deputy director of the National Economic Council. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los ...
Approximately 3.2 million Americans suffering from cancer, heart disease, and other serious or life-threatening diseases benefit from home infusion therapy. As the name suggests, home infusion therapy ...
The author argues that North Carolina's economic success is due to policies that encourage private-sector growth and innovation. Government-imposed price controls, particularly on prescription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results